Peter Radovich M.B.A., Ph.D. Net Worth

The estimated Net Worth of Peter Radovich is at least 2.54 百万$ dollars as of 25 March 2024. Mr Radovich owns over 4,303 units of Mirum Pharmaceuticals Inc stock worth over 1,215,935$ and over the last 9 years he sold MIRM stock worth over 798,421$. In addition, he makes 524,849$ as Chief Operating Officer at Mirum Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr D MIRM stock SEC Form 4 insiders trading

Mr has made over 11 trades of the Mirum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 4,303 units of MIRM stock worth 111,017$ on 25 March 2024.

The largest trade he's ever made was exercising 30,000 units of Mirum Pharmaceuticals Inc stock on 23 January 2018 worth over 48,300$. On average, Mr trades about 2,272 units every 85 days since 2015. As of 25 March 2024 he still owns at least 29,013 units of Mirum Pharmaceuticals Inc stock.

You can see the complete history of Mr Radovich stock trades at the bottom of the page.

Mr. Peter Radovich M.B.A., Ph.D. biography

Peter Radovich M.B.A., Ph.D. is the Chief Operating Officer at Mirum Pharmaceuticals Inc.

What is the salary of Mr D?

As the Chief Operating Officer of Mirum Pharmaceuticals Inc, the total compensation of Mr D at Mirum Pharmaceuticals Inc is 524,849$. There are 6 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of 6,235,180$.

How old is Mr D?

Mr D is 43, he's been the Chief Operating Officer of Mirum Pharmaceuticals Inc since . There are 17 older and 2 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.

What's Mr D's mailing address?

Peter's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY, CA, 94404.

Insiders trading at Mirum Pharmaceuticals Inc

Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over 10,912,565$ worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth 117,972,829$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of 4,538,937$. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth 9,563$.

What does Mirum Pharmaceuticals Inc do?

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Complete history of Mr Radovich stock trades at Global Blood Therapeutics、Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc executives and stock owners

Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Christopher Peetz,
  President, Chief Executive Officer, Director
• Michael Grey,
  Chairman of the Board
• Lara Longpre,
  Chief Development Officer
• Pamela Vig,
  Chief Scientific Officer
• Christopher Peetz,
  Pres, CEO & Director
• Dr. Ian Clements,
  Chief Financial Officer
• Peter Radovich M.B.A., Ph.D.,
  Chief Operating Officer
• Laurent Fischer,
  Independent Director
• Laura Brege,
  Independent Director
• Niall ODonnell,
  Independent Director
• Edward Mathers,
  Independent Director
• Patrick Heron,
  Independent Director
• Tiba Aynechi,
  Director
• Edwin Tucker,
  Chief Medical Officer
• Ian Clements,
  Chief Financial Officer
• Vinita P. Kumar,
  Sr. vice Pres of Quality
• Lara Longpre MBA, MSC,
  Chief Devel. Officer
• Dr. Pamela Vig Ph.D.,
  Head of R&D
• Erin Campany,
  Sr. VP of HR
• Dr. Edwin Jonathan Tucker M.D.,
  Chief Medical Officer
• Paul K. Ross,
  Chief Compliance Officer
• Lara Longpre MSC, MBA,
  Chief Devel. Officer
• Carol L Brosgart,
  Director
• Holdings A/S Novo,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Niall O'donnell,
  Director
• Peter W. Sonsini,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ali Behbahani,
  10% owner
• Forest Baskett,
  10% owner
• Joshua Makower,
  10% owner
• David M Mott,
  10% owner
• Paul Edward Walker,
  10% owner
• Life Sciences Ix, L.P.Fhmls...,
  
• Carmen Chang,
  10% owner
• Scott D Sandell,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• James E Deerfield Mgmt Hif,...,
  
• Enterprise Associates 16, L...,
  10% owner
• William Fairey,
  
• Timothy P Walbert,
  
• Joanne Quan,
  CHIEF MEDICAL OFFICER
• Saira Ramasastry,
  
• James E Deerfield Mgmt Hif,...,
  
• Lon Cardon,
  
• Partners 16, L.P.Nea 16 Gp,...,
  
• Jolanda Howe,
  SVP, GLOBAL CONTROLLER
• Eric Bjerkholt,
  CHIEF FINANCIAL OFFICER
• Peter Radovich,
  PRESIDENT AND COO